Frost & Sullivan Independent Equity Research

BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

bioline

Company: BioLineRx        

Sector: Pharmaceuticals

Report type: Quarterly update, Q3 report

For all past reports click here

Published on: December 19, 2017

View Fullscreen

Download full report